Table 2. Baseline demographics of participants lost to follow-up over 5 years (n = 446).
| Final timepoint with available data for each participant | ||||||||
|---|---|---|---|---|---|---|---|---|
| T1 (n = 72) |
T2 (n = 40) |
T3 (n = 55) |
T4 (n = 65) |
T5 (n = 63) |
T6 (n = 46) |
T7 (n = 49) |
T8 (n = 56) |
|
| Age at entry | 22.8 ± 3.3 | 20.7 ± 3.2 | 21.5 ± 3.1 | 21.0 ± 3.3 | 21.1 ± 3.3 | 20.9 ± 3.3 | 20.7 ± 2.6 | 20.4 ± 2.6 |
| Gender (female) | 33 (46%) | 20 (50%) | 30 (55%) | 42 (65%) | 28 (44%) | 25 (54%) | 34 (69%) | 35 (63%) |
| T1 SOFAS | 59.5 ± 13.6 | 61.2 ± 9.7 | 61.9 ± 8.7 | 58.8 ± 9.2 | 63.3 ± 9.0 | 58.4 ± 6.7 | 60.6 ± 9.0 | 60.2 ± 9.0 |
| T1 Psychotic dx | 23 (32%) | 3 (8%) | 5 (9%) | 4 (6%) | 5 (8%) | 3 (7%) | 3 (6%) | 4 (7%) |
| T1 ND dx | 3 (4%) | 4 (10%) | 0 (0%) | 2 (3%) | 2 (3%) | 3 (7%) | 2 (4%) | 0 (0%) |
| Alcohol AFU | 14.9 ± 2.5 | 15.4 ± 1.9 | 15.5 ± 2.2 | 15.1 ± 2.1 | 15.3 ± 2.4 | 14.4 ± 2.4 | 15.0 ± 2.5 | 15.1 ± 2.9 |
| Tobacco AFU | 15.9 ± 3.2 | 16.0 ± 2.3 | 14.8 ± 2.8 | 16.0 ± 2.6 | 16.3 ± 3.3 | 14.7 ± 2.5 | 15.1 ± 2.7 | 15.3 ± 2.7 |
| Cannabis AFU | 16.3 ± 3.0 | 16.2 ± 2.1 | 16.5 ± 2.6 | 16.3 ± 2.6 | 16.9 ± 2.6 | 15.1 ± 2.2 | 15.7 ± 2.0 | 16.4 ± 3.2 |
| ATS AFU | 18.1 ± 2.9 | 17.3 ± 2.7 | 18.3 ± 2.5 | 17.7 ± 2.7 | 18.3 ± 2.7 | 17.6 ± 2.6 | 17.6 ± 2.3 | 17.8 ± 2.5 |
T1 = service entry; T2 = 3-months; T3 = 6-months; T4 = 1-year; T5 = 2-years; T6 = 3-years; T7 = 4-years; T8 = 5-years; Psychotic dx = psychotic disorder; ND dx = neurodevelopmental diagnosis; ATS = amphetamine-type stimulant; AFU = age of first use